Roopa Industries Share Price

Roopa Industries Limited, with its corporate operations in Hyderabad, functions as an active pharma ingredient and chemical manufacturing company in India. The company was incorporated in 1985 and is part of the TGV Group, a reputed conglomerate in India. Roopa Industries manufactures and exports Chloro Alkali Products, Castor Oil Derivatives, Fatty Acids and Water Treatment Chemicals, and is focused on its core business of Triphenyl Phosphine (TPP) and its allied products. The company has been manufacturing Neutraceuticals, Fine chemicals, Drug Intermediates and Bulk Drugs since 1998, with its TPP project located in Patancheru, Medak District, Telangana.

Roopa Industries share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical and specialty chemical sector. The company’s financial health depends on production volumes, raw material costs, capacity utilization of the TPP project, export demand, and the performance of its chemical and API segments. Roopa Industries stock price is influenced by various factors such as earnings, fluctuations in chemical prices, regulatory changes in the pharmaceutical industry, and global API demand trends. In the longer run, strategies such as stabilizing operations of the TPP project, improving product mix, and expanding into new chemical derivatives affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Roopa Industries live share price provides real time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Roopa Industries live price helps in observing short term price volatility and shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring Roopa Industries stock price movements helps investors understand real time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Roopa Industries Limited Company Fundamentals

a. Company Background

Roopa Industries Limited was incorporated in 1985 and is engaged in the manufacturing and sale of bulk drugs, intermediaries, fine chemicals, and pharmaceutical products. The company operates primarily in the pharmaceutical and chemical manufacturing segment, supplying products such as triphenyl phosphine (TPP), abacavir sulphate, d-penicillamine, s-octabase, DCC, DPA 3, glucosamine, and bromine and its derivatives. Its manufacturing operations are based in India, with the TPP project located in Patancheru, Medak District, Telangana, while corporate functions are managed from its administrative offices in Hyderabad. Over time, the company has focused on stabilizing its TPP operations and improving performance.

Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in pharmaceutical and chemical industries, and input cost fluctuations.

b. Company Product Lines

• Triphenyl Phosphine (TPP) and Allied Products

• Focuses on core business of TPP, a key reagent used in organic synthesis and pharmaceutical manufacturing.

• Bulk Drugs and Drug Intermediates

• Manufactures abacavir sulphate, d-penicillamine, s-octabase, DCC, DPA 3, and other pharmaceutical intermediates.

• Fine Chemicals and Nutraceuticals

• Produces fine chemicals, neutraceuticals, and specialty chemical products for various industries.

• Chloro Alkali, Castor Oil Derivatives, Fatty Acids, Water Treatment Chemicals

• Engages in manufacturing these industrial chemicals for export and domestic markets.

The product portfolio is structured to serve both pharmaceutical companies and industrial chemical buyers.

c. Company Revenue Model

• Domestic Chemical Sales

• Revenue generated through sale of TPP, fine chemicals, and other products to Indian pharmaceutical and industrial customers.

• Export Sales

• Contribution from international customers requiring pharmaceutical intermediates and specialty chemicals.

• Bulk Drug Manufacturing

• Income from contract manufacturing of pharmaceutical ingredients and intermediates.

Revenue performance is primarily influenced by demand for chemical products, raw material costs, and selling price realizations in domestic and export markets.

d. Geographic Presence

• Manufacturing Facility

• Primary TPP project located at Patancheru, Medak District, Telangana, India.

• Corporate Office

• Administrative and management functions based in Hyderabad, Telangana, India.

• Distribution Network

• Domestic distribution across India through direct supply to pharmaceutical and chemical customers.

• Export Markets

• Products are supplied to select international markets depending on demand conditions.

e. Key Milestones

• 1985: Incorporation of Roopa Industries Limited.

• 1998: Diversification into neutraceuticals, fine chemicals, drug intermediates and bulk drugs.

• Recent years: TPP project stabilized at Patancheru and focus on improving performance.

f. Industry Perspective

The pharmaceutical manufacturing industry is highly regulated and capital intensive, closely linked to demand from drug formulation companies and healthcare sectors. Demand trends are influenced by patent expiries, generic drug demand, and growth in pharmaceutical consumption globally. The industry is also affected by fluctuations in raw material prices, regulatory approvals from drug authorities, and quality compliance requirements. Companies in the sector must manage regulatory requirements and cost volatility while maintaining GMP standards. These factors collectively influence financial performance and investor perception of firms like Roopa Industries.

Roopa Industries Limited Stock Market Presence: Listings & Index Representation

Roopa Industries Limited is listed on the National Stock Exchange under the symbol ROOPAIND and on the Bombay Stock Exchange with the scrip code 530991. Roopa Industries share price is actively traded on both exchanges. The company’s market presence is within the micro cap segment of the market. Due to its size and sector focus, Roopa Industries share price is generally tracked by investors interested in the pharmaceutical and specialty chemical industry.

Roopa Industries Limited is not a constituent of major benchmark indices like the Sensex or Nifty 50. The company’s market capitalization places it in the smaller segment of listed companies on both exchanges. Roopa Industries stock price finds limited representation in sector specific indices due to its small scale of operations. Roopa Industries stock price is monitored by market participants who track the pharmaceutical and chemical sector. Roopa Industries stock price movements help investors track the company’s performance relative to other API manufacturers. Roopa Industries stock price serves as a reference point for understanding micro cap pharmaceutical companies.

Roopa Industries Limited Stock Performance and Share Price History

Roopa Industries share price today on the NSE reflects its position as an active pharma ingredient and chemical manufacturer in India. Its performance is qualitatively driven by factors such as production capacity utilization of the TPP project, management of raw material costs, growth in export sales, and the ability to control operational expenses. Investors compare Roopa Industries movement with other pharmaceutical and chemical companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings–driven price changes. Broader sector strength has also supported Roopa Industries at certain times. Beyond operational and sector influences, corporate actions such as board appointments and stabilization of the TPP project can significantly affect share price movements by shaping future growth expectations. This shows how operational improvements may trigger short term swings, even within a regulatory environment influenced by API price cycles and regulatory approvals.

While short term movements respond to events and announcements, longer term valuation trends are better captured by Roopa Industries annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger API demand and stable margins, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of regulatory policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance.

Roopa Industries behavior mirrors the trading patterns of a micro cap pharmaceutical company within India’s API manufacturing ecosystem. The company’s focus on TPP and allied products has shaped its price history. Over time, Roopa Industries has experienced periods of sharp gains followed by phases of consolidation. Roopa Industries has shown higher volatility compared to the broader market, reflecting the cyclical nature of the pharmaceutical industry.

The company’s performance has closely tracked India’s pharmaceutical demand and API price cycles. Positive momentum appeared during periods of strong demand for pharmaceutical intermediates. However, periods of high raw material costs and competitive pressure from larger API players have led to consolidation in Roopa Industries share price. Profitability has faced pressure due to fluctuations in chemical prices and intense competition, though profit before tax improved from the previous year.

Despite industry disruptions, Roopa Industries share price showed resilience during certain recovery phases. While the broader pharmaceutical sector faced supply chain challenges, the company’s stabilization of the TPP project helped Roopa Industries share price maintain some stability. Roopa Industries share price responded to the company’s efforts to improve performance and strengthen its position as part of the TGV Group.

Roopa Industries share price has declined for several recurring reasons. A drop in API demand or lower chemical realizations directly impacts profitability and leads to selling pressure. Changes in government policy on drug price control or export incentives can also cause Roopa Industries share price to fall. Moreover, increases in operational costs such as raw material procurement or energy expenses without matching price increases squeeze margins, making Roopa Industries share price less attractive. Periods of global economic slowdown that affect pharmaceutical consumption raise concerns about API volumes, leading to price declines. Roopa Industries share price is sensitive to raw material price movements. Broader market sell offs in micro cap stocks also pull the price down, regardless of the company’s individual performance. Lower capacity utilization or reduced sales in any product category directly hurts revenue, resulting in a lower valuation. Roopa Industries share price also faces pressure when net profit declines, as seen in recent quarters.

Roopa Industries has seen downward pressure when the company reported fluctuations in profitability. Roopa Industries movements often mirror the broader BSE Healthcare index trends. Roopa Industries can be impacted by changes in chemical prices and regulatory approvals. Roopa Industries has historically shown sensitivity to economic cycles. Roopa Industries may also be affected by the company’s ability to maintain its TPP project operations at optimum capacity. Roopa Industries performance is closely watched by investors tracking the micro cap pharmaceutical segment.

Roopa Industries Limited Investor Relevance and Role in Portfolio

Roopa Industries Limited is a holding in micro cap and pharmaceutical sector portfolios, offering exposure to active pharma ingredient manufacturing, fine chemicals, and pharmaceutical intermediates. Its inclusion in healthcare indices underscores its importance in India’s API manufacturing space. The company’s position as a focused API manufacturer with a stabilized TPP project makes it a consideration for long term allocations.

Roopa Industries share price is influenced by the company’s ownership structure. Roopa Industries’ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable stake of around forty eight percent, reflecting strong internal control as part of the TGV Group. Tumbalam Gooty Raghavendra serves as Managing Director, and Vishnu Vardhan Bhimaneni serves as Chief Executive Officer. Foreign institutional investors hold a very small fraction. Domestic institutional investors hold a negligible stake. The public holds the remaining stake of around fifty one percent. The company has 78,65,520 equity shares of Rs.10 each. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing.

Beyond fundamentals and ownership, Roopa Industries share price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, export orders, and regulatory policy actions. Roopa Industries stock price is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements.

Technical indicators provide additional insight into short term momentum shifts in Roopa Industries share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. The company’s debt to equity ratio reflects a moderate use of leverage. Return on equity and return on capital employed are at modest levels, and the company’s book value per share is a reference point for valuation.

Overall, Roopa Industries demonstrates a higher volatility profile compared to the broader market, with the stock generally considered to have above average systematic risk. This makes it more sensitive to broader market movements and sector specific factors such as API price fluctuations and regulatory compliance costs.

Roopa Industries Limited Sectoral Relevance and Peer Positioning

Roopa Industries Limited sector relevance stems from its four decade presence in the pharmaceutical and chemical industry, its position as part of the TGV Group, a reputed conglomerate in India, its focus on core business Triphenyl Phosphine (TPP) and its allied products, its product portfolio covering bulk drugs, API intermediates (abacavir sulphate, d-penicillamine, s-octabase, DCC, DPA 3), fine chemicals, neutraceuticals, chloro alkali products, castor oil derivatives, fatty acids, water treatment chemicals, and bromine and its derivatives, its TPP project in Patancheru, Medak District, Telangana, and its manufacturing operations since 1998, establishing it as a focused micro cap API provider supporting India’s pharmaceutical and chemical ecosystem. Peer comparisons with companies like Sree Rayalaseema Hi Strength Hypo Limited, Medicamen Biotech, and other micro cap API manufacturers focus on production capacity, product mix, export presence, and value-added product diversification rather than short term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API prices, pharmaceutical demand trends, and government drug policies further highlights Roopa Industries positioning within India’s broader pharmaceutical manufacturing market.

Roopa Industries market cap highlights its position as a micro cap player within India’s pharmaceutical sector. The company’s market capitalization has moved in line with investor perceptions of the company’s growth potential following the stabilization of its TPP project. From earlier periods through more recent times, the market cap showed trends reflecting API demand cycles. This pattern reflects investor confidence during favourable pharmaceutical demand periods, followed by contraction during challenging periods impacted by raw material cost inflation and competitive pressures. This movement mirrors the correction in Roopa Industries share price from its annual high to recent levels.

Roopa Industries earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal periods, total income showed trends supported by the core TPP and API business. The company’s revenue from operations showed moderate growth. Profit before tax stood at Rs. 272.17 lakhs compared to Rs. 217.39 lakhs for the previous year. Profit after tax stood at Rs.203.49 lakhs. The company has faced headwinds from fluctuating chemical prices and increased competitive pressures. However, the company has stabilized its TPP project operations and continues to focus on improving performance. These developments illustrate the cyclical nature of the API manufacturing industry and the company’s position within this sector.

Roopa Industries EPS provides insight into its operational performance and income generation from API and chemical sales. The company reported earnings that varied based on chemical cycles and pharmaceutical demand. The earnings per share has shown fluctuations reflecting the company’s operating leverage. The company has a face value of ten rupees per share. More recent quarterly performance suggests that EPS has shown variability as the company navigates market conditions, with net profit decline in recent quarters.

Roopa Industries P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API and chemical sales. The current valuation compared to industry averages indicates how the market assesses the company’s earnings potential. The company’s profit after tax has shown fluctuations across different fiscal periods based on operational performance. However, periodic performance has shown changes on a quarter on quarter basis depending on pharmaceutical demand. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical industry.

Summary

Roopa Industries Limited operates as an active pharma ingredient and chemical manufacturer under the TGV Group. The company focuses on Triphenyl Phosphine (TPP) production along with bulk drugs and fine chemicals. Roopa Industries share price reflects market perceptions of API demand and pharmaceutical sector conditions. Roopa Industries stock price movements are influenced by chemical price cycles, regulatory approvals, and the company’s ability to maintain TPP project operations at optimum capacity.